Abstract
Psychostimulant addiction is associated with dysfunctions in frontal cortex. Previous data demonstrated that repeated exposure to methamphetamine (METH) can alter prefrontal cortex (PFC)-dependent functions. Here, we show that withdrawal from repetitive non-contingent METH administration (7 days, 1 mg/kg) depressed voltage-dependent calcium currents (ICa ) and increased hyperpolarization-activated cation current (IH ) amplitude and the paired-pulse ratio of evoked excitatory postsynaptic currents (EPSCs) in deep-layer pyramidal mPFC neurons. Most of these effects were blocked by systemic co-administration of the D1/D5 receptor antagonist SCH23390 (0.5 and 0.05 mg/kg). In vitro METH (i.e. bath-applied to slices from naïve-treated animals) was able to emulate its systemic effects on ICa and evoked EPSCs paired-pulse ratio. We also provide evidence of altered mRNA expression of (1) voltage-gated calcium channels P/Q-type Cacna1a (Cav 2.1), N-type Cacna1b (Cav 2.2), T-type Cav 3.1 Cacna1g, Cav 3.2 Cacna1h, Cav 3.3 Cacna1i and the auxiliary subunit Cacna2d1 (α2δ1); (2) hyperpolarization-activated cyclic nucleotide-gated channels Hcn1 and Hcn2; and (3) glutamate receptors subunits AMPA-type Gria1, NMDA-type Grin1 and metabotropic Grm1 in the mouse mPFC after repeated METH treatment. Moreover, we show that some of these changes in mRNA expression were sensitive D1/5 receptor blockade. Altogether, these altered mechanisms affecting synaptic physiology and transcriptional regulation may underlie PFC functional alterations that could lead to PFC impairments observed in METH-addicted individuals.
Keywords:
Dopamine receptors; glutamate; methamphetamine; prefrontal cortex; voltage-gated calcium channels.
© 2015 Society for the Study of Addiction.
Publication types
-
Research Support, N.I.H., Extramural
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Animals
-
Benzazepines / pharmacology
-
Calcium / metabolism*
-
Calcium Channels / drug effects
-
Calcium Channels / genetics
-
Calcium Channels, N-Type / drug effects
-
Calcium Channels, N-Type / genetics
-
Calcium Channels, T-Type / drug effects
-
Calcium Channels, T-Type / genetics
-
Dopamine Uptake Inhibitors / pharmacology*
-
Hyperpolarization-Activated Cyclic Nucleotide-Gated Channels / drug effects
-
Hyperpolarization-Activated Cyclic Nucleotide-Gated Channels / genetics
-
Male
-
Methamphetamine / pharmacology*
-
Mice
-
Nerve Tissue Proteins / drug effects
-
Nerve Tissue Proteins / genetics
-
Potassium Channels / drug effects
-
Potassium Channels / genetics
-
Prefrontal Cortex / drug effects*
-
Prefrontal Cortex / metabolism
-
Pyramidal Cells / drug effects*
-
Pyramidal Cells / metabolism
-
RNA, Messenger / drug effects*
-
RNA, Messenger / metabolism
-
Receptors, AMPA / drug effects
-
Receptors, AMPA / genetics
-
Receptors, Dopamine D1 / antagonists & inhibitors
-
Receptors, Dopamine D1 / metabolism*
-
Receptors, Dopamine D5 / antagonists & inhibitors
-
Receptors, Dopamine D5 / metabolism*
-
Receptors, N-Methyl-D-Aspartate / drug effects
-
Receptors, N-Methyl-D-Aspartate / genetics
-
Synaptic Transmission / drug effects*
Substances
-
Benzazepines
-
CACNA2D1 protein, mouse
-
Cacna1b protein, mouse
-
Cacna1g protein, mouse
-
Cacna1h protein, mouse
-
Cacna1i protein, mouse
-
Calcium Channels
-
Calcium Channels, N-Type
-
Calcium Channels, T-Type
-
Dopamine Uptake Inhibitors
-
Gprin1 protein, mouse
-
Hcn1 protein, mouse
-
Hcn2 protein, mouse
-
Hyperpolarization-Activated Cyclic Nucleotide-Gated Channels
-
Nerve Tissue Proteins
-
Potassium Channels
-
RNA, Messenger
-
Receptors, AMPA
-
Receptors, Dopamine D1
-
Receptors, N-Methyl-D-Aspartate
-
SCH 23390
-
voltage-dependent calcium channel (P-Q type)
-
Receptors, Dopamine D5
-
Methamphetamine
-
Calcium
-
glutamate receptor ionotropic, AMPA 1